Loading news...
Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late
Campbell and CO Investment Adviser LLC bought a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,281 shares of the biotechnology company's stock, valued at approximately $560,000. Campbell and CO Investment
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.
The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as reported.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Paul Lizzul sold 3,650 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares of the company's stock,
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 14,281 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares of the
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 9,639 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.56, for a total transaction of $439,152.84. Following the completion of the transaction, the insider owned 9,157 shares in the company, valued
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 9,202 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sales of the cancer drug Jemperli.
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 10,000 shares of the company's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $46.00, for a total value of $460,000.00. Following the transaction, the insider directly owned 9,088 shares in the company, valued at $418,048.
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations.
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75.0 million Stock Repurchase Plan of which Anaptys has repurchased a total of 3,443,188 shares of common stock (11.2% shares outstanding before the start of this repurchase plan). Excluding any additional potential purchases under this Stock Repurchase Plan, Anaptys anticipates ending 2025 with approximately $300 million in cash, cash equivalents and investments, including an anticipated accrual of a one-time $75 million commercial sales milestone in Q4 2025 due from GSK once Jemperli achieves $1 billion in worldwide net sales.